ArticleScientific reports2026
Tear fluid as a novel specimen for detection of alpha-synuclein seeding activity in Parkinson's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) is a clinically heterogeneous neurodegenerative disorder characterized by intraneuronal accumulation of misfolded α-synuclein. Real-time quaking-induced conversion (RT-QuIC) detects seeding-competent αSyn species but commonly relies on invasive matrices. We evaluated tear fluid (TF) as a non-invasive biofluid for αSyn RT-QuIC in 44 PD patients and 32 matched healthy controls (HCs). ROC analyses were performed on participant-level readouts (mean of four technical replicates), and optimal cut-offs were selected using the Youden index before being applied to each technical replicate. At the subject level, the best trade-offs were observed at maximum fluorescence (MaxRFU) ≥ 2/4 (sensitivity 59.1%; specificity 65.6%), MedianRFU ≥ 3/4 (sensitivity 40.9%; specificity 78.1%), and area under fluorescence curve (AUFC) ≥ 3/4 (sensitivity 47.7%; specificity 71.9%). In a sensitivity analysis excluding RT-QuIC positive HCs with potential prodromal/risk features, specificity increased to 75% (MaxRFU), 86.2% (MedianRFU), and 79.3% (AUFC). Assay-characterization analyses, performed including all technical replicates, showed significantly higher fluorescence signals throughout the RT-QuIC amplification curve (p < 0.0001) with shorter lag phase, higher MedianRFU and MaxRFU, and larger AUFC values in PD than in HCs (all p < 0.05). Exploratory subgroup analyses suggested possible phenotype-related variability in test response. Our findings suggest that αSyn seeding activity may be detected in TF. Despite suboptimal sensitivity, non-invasiveness and promising specificity support further optimization of TF-based RT-QuIC as a diagnostic tool for synucleinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.